Those with diabetes were also more likely than those without diabetes to receive statins (89% vs 82%, p<0.001), ACE inhibitors/ARBs (78% vs 72%, p<0.001) and β-blockers (74% vs 71%, p<0.001). Here, ACE is linked to diabetes mellitus.